Your browser doesn't support javascript.
loading
Triple-Negative Breast Cancer Intrinsic FTSJ1 Favors Tumor Progression and Attenuates CD8+ T Cell Infiltration.
Sun, Yangqing; Liu, Qingqing; Zhong, Shangwei; Wei, Rui; Luo, Jun-Li.
Afiliación
  • Sun Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Liu Q; Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Zhong S; The Cancer Research Institute and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
  • Wei R; Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Luo JL; Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
Cancers (Basel) ; 16(3)2024 Jan 31.
Article en En | MEDLINE | ID: mdl-38339348
ABSTRACT
FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) is a member of the methyltransferase superfamily and is involved in the processing and modification of ribosomal RNA. We herein demonstrate that FTSJ1 favors TNBC progression. The knockdown of FTSJ1 inhibits TNBC cell proliferation and development, induces apoptosis of cancer cells, and increases the sensitivity of TNBC cells to T-cell-mediated cytotoxicity. Furthermore, the high expression of FTSJ1 in TNBC attenuates CD8+T cell infiltration in the tumor microenvironment (TME) correlated with poorer prognosis for clinical TNBC patients. In this study, we establish that FTSJ1 acts as a tumor promotor, is involved in cancer immune evasion, and may serve as a potential immunotherapy target in TNBC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: China